Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Set to be Used in Multi-Billion Dollar Markets; On Track to have 2023 as Best Year Yet

  • Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats
  • This unique approach to drug delivery has earned Lexaria a total of 35 patents, with many patents pending worldwide
  • The company continues active discussions with multi-billion dollar companies for the potential use of DehydraTECH in their commercial pursuits
  • Lexaria is also actively seeking commercial partners during 2023 and 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is out on an ambitious move to address conditions with high unmet needs. This focus has allowed them to make strides in the potential treatment of conditions such as hypertension, epilepsy, human hormone delivery, and nicotine replacement; all made possible through its patented technology, DehydraTECH(TM).

DehydraTECH enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats. The technology serves as an additional step that can be easily incorporated into any formulation and manufacturing process, allowing for speedy delivery, an increase in bioavailability, and an increase in brain absorption, among other advantages (

Lexaria’s studies have demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,700 percent, which has opened the technology up to new possibilities for improved drug delivery.

One stand-out feature of DehydraTECH is its ability to work symbiotically with existing physiological systems to enable masking oral and olfactory receptors, rendering DehydraTECH-processed compounds mostly flavorless and odorless. This results in formulations not requiring sweeteners or chemical masking agents for flavor and odor blocking, meaning that manufacturers can create low-sugar products with fewer calories while avoiding excessive artificial sweeteners.

Once ingested, the compounds, through the help of fatty acids, permeate the intestinal wall for the active payload, then are transported to the systemic circulation by one of two pathways, typically dependent on the type of fatty acid(s) chosen for a given formulation. For hepatic transport, or where liver metabolism is desirable for biotransformation of the payload, Lexaria’s methodology uses medium-chain fatty acids. For lymphatic transport, on the other hand, Lexaria uses long-chain fatty acids, which are absorbed via the lymphatic lacteals, ultimately diverting them away from the liver and entering the general circulation very quickly.

DehydraTECH and its unique approach to drug delivery have earned Lexaria a current total of 35 patents across the United States, Canada, Mexico, Australia, Japan, India, and the European Union. Although it has already achieved considerable intellectual property protection through its existing patent portfolio, the company has a number of additional patents pending worldwide. These achievements have sparked interest across various industries. Lexaria’s CEO, Chris Bunka, has noted the company’s active discussions with multi-billion dollar companies for the potential use of its technology in their commercial product pursuits.

“Our applied R&D is paying off in spades because we are currently in active discussions with several multi-billion dollar companies around the world for the potential use of Lexaria’s DehydraTECH technology in their commercial product pursuits,” noted Mr. Bunka.

“These discussions are ongoing and have thus helped us to meet one of our primary objectives of the last year, which is to introduce DehydraTECH to world-leading potential collaborators,” he added (

Lexaria is ambitious in its push for DehydraTECH and is currently seeking commercial partners to use the technology in what are usually multi-billion-dollar markets. The company is taking steps to have multiple choices in how to fund its operations, and so far, it is on track to have 2023 as its best year ever.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

This entry was posted in Lexaria Bioscience Corp. LEXX. Bookmark the permalink.

Comments are closed.